PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16845716-11	2006	Whereas, in PGZ treatment group, serum levels of AST and FINS showed decreasing tendency, liver indexes, serum levels of ALT, ALP, TNF-alpha and HOMA-IR were significantly decreased compared with model group II.	Pioglitazone	12-15	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	49-52	
20005349-8	2009	RESULTS: Pioglitazone pretreatment significantly reduced liver enzyme content (ALT, 176.80 +/- 13.75 vs 235.28 +/- 31.92 and AST, 748.20 +/- 79.29 vs 944.85 +/- 101.87) and TNF-alpha level (9:8.60 +/- 8.67 vs 138.28 +/- 9.99) after I/R compared with the control group.	Pioglitazone	9-21	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	125-128	
20005349-11	2009	CONCLUSION: The present study showed that pioglitazone administration improved hepatic I/R injury that was associated with enhanced antioxidant enzyme activities and suppression of TNF-alpha, ALT, and AST levels.	Pioglitazone	42-54	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	201-204	
26064395-7	2015	JLD or pioglitazone administration ameliorated fasting plasma levels of glucose, insulin, triglyceride (TG), total cholesterol (TC), ALT, AST and non-esterified fatty acid (NEFA) (P < 0.05).	Pioglitazone	7-19	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	138-141